

Site Number: _____ Screening ID: _____ - ____ First 3 Letters of First Name: _____

Complete this form when a study participant stops taking the coded study medication, regardless of the circumstances of withdrawal of study medication.

A. REPORT INFORMATION

1. Date of report: _____ / _____ / _____
MM DD YYYY

2. Visit the study medication was withdrawn, or which was the last scheduled visit the participant attended before medication was withdrawn? (*check one*)

- | | | | |
|-----------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|
| <input type="checkbox"/> 3 Week 1 | <input type="checkbox"/> 7 Month 2 | <input type="checkbox"/> 17 Month 12 | <input type="checkbox"/> 29 Month 24 |
| <input type="checkbox"/> 4 Week 2 | <input type="checkbox"/> 8 Month 3 | <input type="checkbox"/> 20 Month 15 | |
| <input type="checkbox"/> 5 Week 3 | <input type="checkbox"/> 11 Month 6 | <input type="checkbox"/> 23 Month 18 | |
| <input type="checkbox"/> 6 Week 4 | <input type="checkbox"/> 14 Month 9 | <input type="checkbox"/> 26 Month 21 | |

B. STUDY MEDICATION WITHDRAWAL INFORMATION

1. Date study medication withdrawal became effective: _____ / _____ / _____
MM DD YYYY

2. Reason the coded study medication was stopped (*check one*):

- | | |
|---|--|
| <input type="checkbox"/> 1 Completion of 2-year follow-up period | <input type="checkbox"/> 7 Participant plans on fathering a child |
| <input type="checkbox"/> 2 Participant ineligible for participation | <input type="checkbox"/> 8 Need to start other immunosuppressive medications (<i>such as systemic steroids</i>) |
| <input type="checkbox"/> 3 Participant withdrew consent | <input type="checkbox"/> 9 Participant develops a medical condition that is a contraindication to experimental treatment |
| <input type="checkbox"/> 4 Intercurrent need for unapproved vaccine | <input type="checkbox"/> 10 Clinically significant change in EBV or CMV status |
| <input type="checkbox"/> 5 Adverse effect of immunosuppression | <input type="checkbox"/> 99 Other |
| <input type="checkbox"/> 6 Pregnancy | |

IF OTHER, a. Specify: _____

3. Was the participant told of his/her treatment group assignment? Y N

With the exception of a pregnancy, if the participant was told of his/her treatment group assignment the Protocol Deviation Form (MMF11) must be completed

4. Has the participant's unused study medication been returned to the clinic? Y N

5. Did the participant complete the planned 2-year follow-up period? Y N

IF NO,

a. Is the participant willing to continue with future follow-up visits as scheduled? Y N

b. Does the participant have the option of restarting the study medication at a later date? Y N

Initials (first, middle, last) of person completing this form: _____
F M L

Date form completed: _____ / _____ / _____
MM DD YYYY

On all questions write "?" if the desired information is currently unavailable, but is being checked and will be known in future updates. Write "" if the desired information is permanently unavailable (i.e. will not be known in any future updates).*



MMF-DZB Study
MEDICATION WITHDRAWAL FORM

Form MMF08W

July 06, 2004

Page 2 of 1

Site Number: _____

Screening ID: _____ - ____

First 3 Letters of First Name: _____

On all questions write “?” if the desired information is currently unavailable, but is being checked and will be known in future updates. Write “” if the desired information is permanently unavailable (i.e. will not be known in any future updates).*